ZOLL SEC-arkivering - Zoll Medical Corp- Årsrapport, fuldmagtserklæring, prospekt

Grundlæggende statistik

CIK

887568

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Zoll Medical Corp

SEC Filings (Chronological Order)

Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.

February 11, 2013	SC 13G/A	ZOLL / Zoll Medical Corp / VANGUARD GROUP INC Passive Investment SC 13G/A 1 zollmedicalcorp.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Zoll Medical Corp Title of Class of Securities: COMMON STOCK CUSIP Number: 989922109 Date of Event Which Requires Filing of this Statement: December 31, 2012 Check the appropriate box to designate the rule pursuant to w
February 7, 2013	EX-3	POWER OF ATTORNEY Power of Attorney EXHIBIT 3 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, THAT: The undersigned, Waddell & Reed Financial, Inc.
February 7, 2013	SC 13G/A	ZOLL / Zoll Medical Corp / WADDELL & REED FINANCIAL INC - ZOLL MEDICAL CORPORATION Passive Investment ZOLL Medical Corporation UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 7, 2013	EX-2	EXHIBIT 2 Identification and Classification of the Subsidiary Which Acquired the Security EXHIBIT 2 Waddell & Reed Investment Management Company - Tax ID No. 48-1106973 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940 Ivy Investment Management Company - Tax ID No. 03-0481447 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940
February 7, 2013	EX-1	JOINT FILING AGREEMENT Joint Filing Agreement EXHIBIT 1 JOINT FILING AGREEMENT Waddell & Reed Financial, Inc.
May 9, 2012	SC 13G/A	ZOLL / Zoll Medical Corp / Capital Research Global Investors - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* ZOLL Medical Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 989922109 (CUSIP Number) April 30, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S
May 7, 2012	15-12G	- FORM 15-12G 15-12G 1 d348225d1512g.htm FORM 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-20225 ZOLL MEDICAL CORPORATION (E
May 1, 2012	S-8 POS	- FORM S-8 POS FORM S-8 POS As filed with the Securities and Exchange Commission on April 30, 2012 Registration No.
May 1, 2012	S-8 POS	- FORM S-8 POS As filed with the Securities and Exchange Commission on April 30, 2012 Registration No.
May 1, 2012	S-8 POS	- FORM S-8 POS As filed with the Securities and Exchange Commission on April 30, 2012 Registration No.
May 1, 2012	S-8 POS	- FORM S-8 POS As filed with the Securities and Exchange Commission on April 30, 2012 Registration No.
May 1, 2012	POS AM	- POS AM POS AM As filed with the Securities and Exchange Commission on April 30, 2012 Registration Statement No.
May 1, 2012	S-8 POS	- FORM S-8 POS As filed with the Securities and Exchange Commission on April 30, 2012 Registration No.
May 1, 2012	POS AM	- POS AM POS AM As filed with the Securities and Exchange Commission on April 30, 2012 Registration Statement No.
May 1, 2012	S-8 POS	- FORM S-8 POS FORM S-8 POS As filed with the Securities and Exchange Commission on April 30, 2012 Registration No.
May 1, 2012	S-8 POS	- FORM S-8 POS FORM S-8 POS As filed with the Securities and Exchange Commission on April 30, 2012 Registration No.
May 1, 2012	POS AM	- POS AM POS AM As filed with the Securities and Exchange Commission on April 30, 2012 Registration Statement No.
May 1, 2012	S-8 POS	- FORM S-8 POS FORM S-8 POS As filed with the Securities and Exchange Commission on April 30, 2012 Registration No.
May 1, 2012	S-8 POS	- FORM S-8 POS S-8 POS 1 d343139ds8pos.htm FORM S-8 POS As filed with the Securities and Exchange Commission on April 30, 2012 Registration No. 333-173041 Registration No. 333-157282 Registration No. 333-137245 Registration No. 333-132804 Registration No. 333-120310 Registration No. 333-101839 Registration No. 333-38048 Registration No. 333-68401 Registration No. 333-68403 UNITED STATES SECURITIES AND EXCHANGE C
April 26, 2012	SC 14D9/A	- SCHEDULE 14D-9 AMENDMENT NO. 6 Schedule 14D-9 Amendment No. 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 6) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL MEDICAL CORPORATION (Name of Subject Company) ZOLL MEDICAL CORPORATION (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Cl
April 26, 2012	EX-99.(A)(5)(I)	Completion of the subsequent offering period to acquire ZOLL Medical Corporation English translation of Japanese Press Release Exhibit (a)(5)(I) News Release April 26, 2012 Completion of the subsequent offering period to acquire ZOLL Medical Corporation Asahi Kasei Corp.
April 26, 2012	SC TO-T/A	- AMENDMENT NO. 6 TO SCHEDULE TO Amendment NO. 6 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 6) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL MEDICAL CORPORATION (Name of Subject Company (Issuer)) ASAHI KASEI CORPORATION ASCLEPIUS SUBSIDIARY CORPORATION (Name of Filing Persons (Offerors)) Common Stock, $0.
April 26, 2012	EX-99.(A)(5)(H)	Asahi Kasei Completes Subsequent Offering Period for ZOLL Press Release Exhibit (a)(5)(H) NEWS RELEASE Asahi Kasei Completes Subsequent Offering Period for ZOLL Tokyo, Japan/ New York, NY, U.
April 26, 2012	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing - FORM 8-K FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2012 ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 000-20225 04-2711626 (State or other jurisdiction of incorporation or organizat
April 24, 2012	SC 13D/A	ZOLL / Zoll Medical Corp / GAMCO INVESTORS, INC. ET AL Activist Investment SC 13D/A 1 zoll02.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Zoll Medical Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 989922109 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of
April 23, 2012	EX-99.(A)(5)(F)	Asahi Kasei Announces Completion of Tender Offer and Commencement of a Subsequent Offering Period for ZOLL Press Release Exhibit (a)(5)(F) NEWS RELEASE Asahi Kasei Announces Completion of Tender Offer and Commencement of a Subsequent Offering Period for ZOLL Tokyo, Japan/ New York, NY, U.
April 23, 2012	SC TO-T/A	- AMENDMENT NO. 5 TO SCHEDULE TO Amendment No. 5 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 5) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL MEDICAL CORPORATION (Name of Subject Company (Issuer)) ASAHI KASEI CORPORATION ASCLEPIUS SUBSIDIARY CORPORATION (Name of Filing Persons (Offerors)) Common Stock, $0.
April 23, 2012	SC 14D9/A	- AMENDMENT NO. 5 TO SC14D9 Amendment No. 5 to SC14D9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 5) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL MEDICAL CORPORATION (Name of Subject Company) ZOLL MEDICAL CORPORATION (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class o
April 23, 2012	EX-99.(A)(5)(G)	Outcome of the tender offer for shares of ZOLL Medical Corporation of the US English translation of Japanese Press Release Exhibit (a)(5)(G) April 23, 2012 Outcome of the tender offer for shares of ZOLL Medical Corporation of the US Asahi Kasei Corp.
April 17, 2012	SC 13D/A	ZOLL / Zoll Medical Corp / GAMCO INVESTORS, INC. ET AL Activist Investment SC 13D/A 1 zoll01.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Zoll Medical Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 989922109 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of
April 13, 2012	SC TO-T/A	- AMENDMENT NO. 4 TO SCHEDULE TO AMENDMENT NO. 4 TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 4) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL MEDICAL CORPORATION (Name of Subject Company (Issuer)) ASAHI KASEI CORPORATION ASCLEPIUS SUBSIDIARY CORPORATION (Name of Filing Persons (Offerors)) Common Stock, $0.
April 13, 2012	SC 14D9/A	- AMENDMENT NO.4 TO SC14D9 Amendment No.4 to SC14D9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 4) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL MEDICAL CORPORATION (Name of Subject Company) ZOLL MEDICAL CORPORATION (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of
April 9, 2012	EX-99.(B)(2)	English Language Summary of Debt Financing Agreement, dated April 9, 2012, by and among Asahi Kasei Corporation, UBS AG, Tokyo Branch, Sumitomo Mitsui Banking Corporation and certain lenders party thereto Parties The Lenders, the Borrower and the Fac English Language Summary of Debt Financing Agreement Exhibit (b)(2) English Language Summary of Debt Financing Agreement, dated April 9, 2012, by and among Asahi Kasei Corporation, UBS AG, Tokyo Branch, Sumitomo Mitsui Banking Corporation and certain lenders party thereto Parties The Lenders, the Borrower and the Facility Agent.
April 9, 2012	SC 14D9/A	- SC 14D9/A (AMENDMENT NO. 3) SC 14D9/A (Amendment No. 3) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL MEDICAL CORPORATION (Name of Subject Company) ZOLL MEDICAL CORPORATION (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class
April 9, 2012	SC TO-T/A	- AMENDMENT NO.3 TO SCHEDULE TO Amendment No.3 To Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 3) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL MEDICAL CORPORATION (Name of Subject Company (Issuer)) ASAHI KASEI CORPORATION ASCLEPIUS SUBSIDIARY CORPORATION (Name of Filing Persons (Offerors)) Common Stock, $0.0
April 5, 2012	SC TO-T/A	- AMENDMENT NO.2 TO SCHEDULE TO AMENDMENT NO.2 TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 2) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL MEDICAL CORPORATION (Name of Subject Company (Issuer)) ASAHI KASEI CORPORATION ASCLEPIUS SUBSIDIARY CORPORATION (Name of Filing Persons (Offerors)) Common Stock, $0.0
April 5, 2012	SC 14D9/A	- AMENDMENT NO. 2 TO SCHEDULE 14D-9 Amendment No. 2 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL MEDICAL CORPORATION (Name of Subject Company) ZOLL MEDICAL CORPORATION (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of
April 3, 2012	SC 14D9/A	- AMENDMENT NO. 1 TO SCHEDULE 14D9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL MEDICAL CORPORATION (Name of Subject Company) ZOLL MEDICAL CORPORATION (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 989922109 (C
April 3, 2012	EX-99.(D)(4)	ASAHI KASEI CORPORATION Limited Waiver of Tender and Voting Agreement Exhibit (d)(4) ASAHI KASEI CORPORATION 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo 101-8101, Japan Phone: +81-(0)3-3296-3018 Fax: +81-(0)3-3296-3070 URL: www.
April 3, 2012	SC TO-T/A	- AMENDMENT NO.1 TO SCHEDULE TO Amendment No.1 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 1) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL MEDICAL CORPORATION (Name of Subject Company (Issuer)) ASAHI KASEI CORPORATION ASCLEPIUS SUBSIDIARY CORPORATION (Name of Filing Persons (Offerors)) Common Stock, $0.0
March 30, 2012	SC 13D	ZOLL / Zoll Medical Corp / GAMCO INVESTORS, INC. ET AL Activist Investment SC 13D 1 zoll00.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Zoll Medical Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 989922109 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person Authorized to
March 26, 2012	EX-99.(A)(5)(D)	Notice of Offer to Purchase for Cash All Outstanding Shares of Common Stock ZOLL Medical Corporation $93.00 Net Per Share Asclepius Subsidiary Corporation an indirect wholly-owned subsidiary of Asahi Kasei Corporation Form of summary advertisement Exhibit (a)(5)(D) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below).
March 26, 2012	EX-99.(A)(1)(E)	Offer to Purchase for Cash All Outstanding Shares of Common Stock ZOLL Medical Corporation $93.00 Net Per Share Asclepius Subsidiary Corporation an indirect wholly-owned subsidiary of Asahi Kasei Corporation THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIR Client Letter Exhibit(a)(1)(E) Offer to Purchase for Cash All Outstanding Shares of Common Stock of ZOLL Medical Corporation at $93.
March 26, 2012	EX-99.(D)(2)	Page 2 Confidentiality Agreement, effective as of January 25, 2012 Exhibit (d)(2) PERSONAL AND CONFIDENTIAL January 25, 2012 Asahi Kasei Corporation 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo 101-8101 Japan Attn: Koji Fujiwara, Director & Primary Executive Officer Ladies and Gentlemen: In connection with your consideration of a possible transaction (the “Possible Transaction”) with ZOLL Medical Corporation (the “Company”), you have requested information concerning the Company and its subsidiaries and affiliates.
March 26, 2012	EX-99.(B)(1)	Project Athena – Commitment Letter Commitment Letter, dated March 12, 2012 Exhibit (b)(1) UBS AG, Tokyo Branch East Tower, Otemachi First Square, 5-1, Otemachi 1-Chome Chiyoda-ku, Tokyo 100-0004 Japan Asahi Kasei Corporation 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo 101-8101 Japan For the attention of: Mr.
March 26, 2012	EX-99.(A)(1)(A)	Offer to Purchase for Cash All Outstanding Shares of Common Stock ZOLL Medical Corporation $93.00 Net Per Share Asclepius Subsidiary Corporation an indirect wholly-owned subsidiary of Asahi Kasei Corporation THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIR Offer to Purchase Table of Contents Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of ZOLL Medical Corporation at $93.
March 26, 2012	EX-99.(A)(1)(C)	Notice of Guaranteed Delivery Offer to Purchase for Cash All Outstanding Shares of Common Stock ZOLL Medical Corporation $93.00 Net Per Share Asclepius Subsidiary Corporation an indirect wholly-owned subsidiary of Asahi Kasei Corporation THE OFFER AN Notice of Guaranteed Delivery Exhibit(a)(1)(C) Notice of Guaranteed Delivery for Offer to Purchase for Cash All Outstanding Shares of Common Stock of ZOLL Medical Corporation at $93.
March 26, 2012	SC 14D9	- SCHEDULE 14D-9 Schedule 14D-9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 26, 2012	EX-99.(A)(5)(E)	Asahi Kasei Commences Tender Offer for ZOLL Medical Corporation Press Release regarding commencement of the tender offer issued by Asahi Kasei Exhibit (a)(5)(e) NEWS RELEASE Asahi Kasei Commences Tender Offer for ZOLL Medical Corporation Tokyo, Japan/ New York, NY, U.
March 26, 2012	SC TO-T	- SCHEDULE TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL MEDICAL CORPORATION (Name of Subject Company (Issuer)) ASAHI KASEI CORPORATION ASCLEPIUS SUBSIDIARY CORPORATION (Name of Filing Persons (Offerors)) Common Stock, $0.01 Par Value Per Share (Title of Clas
March 26, 2012	EX-99.(A)(3)	ZOLL Medical Corporation 269 Mill Road Chelmsford, Massachusetts 01824 Letter to the Shareholders of ZOLL Medical Corporation Exhibit (a)(3) ZOLL Medical Corporation 269 Mill Road Chelmsford, Massachusetts 01824 March 26, 2012 Dear Shareholders: We are pleased to inform you that ZOLL Medical Corporation (the “Company”) entered into an Agreement and Plan of Merger, dated as of March 12, 2012 (the “Merger Agreement”), with Asahi Kasei Corporation, a Japanese corporation (“Parent”), Asahi Kasei Holdings US, Inc.
March 26, 2012	EX-99.(A)(1)(D)	Offer to Purchase for Cash All Outstanding Shares of Common Stock ZOLL Medical Corporation $93.00 Net Per Share Asclepius Subsidiary Corporation an indirect wholly-owned subsidiary of Asahi Kasei Corporation THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIR Broker, Dealer Letter Exhibit(a)(1)(D) Offer to Purchase for Cash All Outstanding Shares of Common Stock of ZOLL Medical Corporation at $93.
March 26, 2012	EX-99.(A)(1)(B)	THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. LETTER OF TRANSMITTAL To Tender Shares of Common Stock ZOLL Medical Corporation $93.00 Net Per Share Pursuant to the Offer to Purchase dated March 26, 2012 Asclepius Subsidiary Corpora Letter of Transmittal Exhibit (a)(1)(B) THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.
March 20, 2012	LETTER	LETTER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 DIVISION OF CORPORATION FINANCE March 20, 2012 Via E-Mail Richard A. Packer Chief Executive Officer Zoll Medical Corporation 269 Mill Road Chelmsford, MA 01824 Re: Zoll Medical Corporation Form 10-K for the Fiscal Year Ended October 2, 2011 Filed November 23, 2011 File No. 0-20225 Dear Mr. Packer: We refer you to our comment l
March 12, 2012	EX-99.1	TENDER AND VOTING AGREEMENT Form of Tender and Voting Agreement Exhibit 99.1 EXECUTION COPY TENDER AND VOTING AGREEMENT THIS TENDER AND VOTING AGREEMENT (this “Agreement”) dated as of March 12, 2012 is made by and among Asahi Kasei Corporation, a Japanese corporation (“Parent”), Asahi Kasei Holdings US, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“HoldCo”), Asclepius Subsidiary Corporation, a Massachu
March 12, 2012	8-K	Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2012 ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 000-20225 04-2711626 (State or other jurisdiction of incorporatio
March 12, 2012	SC14D9C	- SCHEDULE 14D-9 Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL Medical Corporation (Name of Subject Company) ZOLL Medical Corporation (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 989922109 (CUSI
March 12, 2012	EX-99.1	Asahi Kasei Announces Agreement to Acquire ZOLL Medical Builds on existing relationship to drive global development of critical care businesses Exhibit 99.1 NEWS RELEASE Asahi Kasei Announces Agreement to Acquire ZOLL Medical Builds on existing relationship to drive global development of critical care businesses Tokyo, Japan/Chelmsford, MA U.S. — March 12, 2012 — Asahi Kasei Corporation (TSE1: 3407, hereinafter: Asahi Kasei), and ZOLL Medical Corporation (NASDAQ GS: ZOLL, hereinafter: ZOLL) today jointly announced that Asahi Kasei, Japan’
March 12, 2012	EX-99.3	Exhibit 99.3 Exhibit 99.3
March 12, 2012	EX-4.1	AMENDMENT SHAREHOLDER RIGHTS AGREEMENT Amendment to the Shareholder Rights Agreement Exhibit 4.1 AMENDMENT TO SHAREHOLDER RIGHTS AGREEMENT This Amendment to Shareholder Rights Agreement (the “Amendment”) is effective as of March 12, 2012, by and between ZOLL Medical Corporation, a Massachusetts corporation (the “Company”), and Computershare Trust Company, N.A., a federally chartered trust company (the “Rights Agent”). WITNESSETH: WHERE
March 12, 2012	EX-2.1	AGREEMENT AND PLAN OF MERGER ZOLL MEDICAL CORPORATION, ASAHI KASEI CORPORATION, ASAHI KASEI HOLDINGS US, INC. ASCLEPIUS SUBSIDIARY CORPORATION March 12, 2012 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 2 Section 1.01 Definitions 2 Section 1.02 Other Agreement and Plan of Merger Exhibit 2.1 AGREEMENT AND PLAN OF MERGER between ZOLL MEDICAL CORPORATION, ASAHI KASEI CORPORATION, ASAHI KASEI HOLDINGS US, INC. and ASCLEPIUS SUBSIDIARY CORPORATION March 12, 2012 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 2 Section 1.01 Definitions 2 Section 1.02 Other Definitional and Interpretative Provisions 10 ARTICLE 2 THE OFFER AND THE MERGER 10 Section 2.01
March 12, 2012	8-A12B/A	- FORM 8-A/A AMENDMENT #1 Form 8-A/A Amendment #1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 12, 2012	SC TO-C	- FORM SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL Medical Corporation (Name of Subject Company (Issuer)) Asahi Kasei Corporation Asclepius Acquisition Corporation (Names of Filing Persons (Offerors)) Common Stock, $0.01 Par Value Per Share (Title of Class of Secur
March 12, 2012	EX-99.2	Asahi Kasei Announces Agreement to Acquire ZOLL Medical Builds on existing relationship to drive global development of critical care businesses Joint Press Release Exhibit 99.2 Asahi Kasei Announces Agreement to Acquire ZOLL Medical Builds on existing relationship to drive global development of critical care businesses Tokyo, Japan/Chelmsford, MA U.S. – March 12, 2012 – Asahi Kasei Corporation (TSE1: 3407, hereinafter: Asahi Kasei), and ZOLL Medical Corporation (NASDAQ GS: ZOLL, hereinafter: ZOLL) today jointly announced that Asahi Kasei,
March 12, 2012	CORRESP	- Correspondence March 12, 2012 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Global Security Risk 100 F Street, N.E. Washington, D.C. 20549-3628 Attn: Cecilia Blye, Chief Re: ZOLL Medical Corporation Form 10-K for Fiscal Year Ended October 2, 2011 Filed November 23, 2011 File No. 0-20225 Dear Ms. Blye: Please find the response of ZOLL Medical Corporation (“ZOLL”
March 12, 2012	EX-99.2	Acquisition of ZOLL Medical Corporation of the US Exhibit 99.2 Reference translation of Japanese news release March 12, 2012 Company name: Asahi Kasei Corp. Name of representative: Taketsugu Fujiwara, President and Representative Director Contact: Yuji Mizuno, Director and Senior Executive Officer Acquisition of ZOLL Medical Corporation of the US Asahi Kasei Corp. (headquarters: Chiyoda Ward, Tokyo; President: Taketsugu Fujiwara) today made an ag
March 12, 2012	SC14D9C	- SCHEDULE 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL Medical Corporation (Name of Subject Company) ZOLL Medical Corporation (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 989922109 (CUSIP Number of Cla
February 28, 2012	LETTER	LETTER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 DIVISION OF CORPORATION FINANCE February 27, 2012 Via E-Mail Richard A. Packer Chief Executive Officer Zoll Medical Corporation 269 Mill Road Chelmsford, MA 01824 Re: Zoll Medical Corporation Form 10-K for the Fiscal Year Ended October 2, 2011 Filed November 23, 2011 File No. 0-20225 Dear Mr. Packer: We have limited our review
February 14, 2012	EX-3	POWER OF ATTORNEY Power of Attorney EXHIBIT 3 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, THAT: The undersigned, Waddell & Reed Financial, Inc.
February 14, 2012	EX-1	JOINT FILING AGREEMENT Joint Filing Agreement EXHIBIT 1 JOINT FILING AGREEMENT Waddell & Reed Financial, Inc.
February 14, 2012	SC 13G	ZOLL / Zoll Medical Corp / WADDELL & REED FINANCIAL INC - ZOLL MEDICAL CORPORATION Passive Investment ZOLL Medical Corporation UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 14, 2012	EX-2	EXHIBIT 2 EX-2 3 d296019dex2.htm IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY EXHIBIT 2 Waddell & Reed Investment Management Company - Tax ID No. 48-1106973 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940 Ivy Investment Management Company - Tax ID No. 03-0481447 Investment Advisor registered under Section 203 of the Investment Advisor
February 14, 2012	SC 13G	ZOLL / Zoll Medical Corp / WELLINGTON MANAGEMENT GROUP LLP - DISCLOSURE DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Zoll Medical Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 989922109 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
February 10, 2012	SC 13G/A	ZOLL / Zoll Medical Corp / BlackRock Inc. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 5) ZOLL MEDICAL CORP - (Name of Issuer) Common Stock - (Title of Class of Securities) 989922109 - (CUSIP Number) December 30, 2011 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
February 10, 2012	8-K	Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 9, 2012 ZOLL MEDICAL CORPORATION (Exact Name of Registrant as Specified in Charter) Massachusetts 000-20225 04-2711626 (State or Other Jurisdiction of Incorporation)
February 10, 2012	SC 13G	ZOLL / Zoll Medical Corp / VANGUARD GROUP INC Passive Investment SC 13G 1 zollmedicalcorp.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.:0 )* Name of issuer: Zoll Medical Corp Title of Class of Securities: Common Stock CUSIP Number: 989922109 Date of Event Which Requires Filing of this Statement: December 31, 2011 Check the appropriate box to designate the rule pursuant to whic
February 8, 2012	SC 13G/A	ZOLL / Zoll Medical Corp / Capital Research Global Investors - SC 13G/A Passive Investment SC 13G/A 1 edgzoll.txt SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Zoll Medical Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 989922109 (CUSIP Number) December 30, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat
February 2, 2012	EX-10.1	RESTRICTED STOCK AWARD AGREEMENT UNDER THE ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2006 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN EX-10.1 2 d264031dex101.htm FORM OF RESTRICTED STOCK AWARD Exhbit 10.1 RESTRICTED STOCK AWARD AGREEMENT UNDER THE ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2006 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN Name of Grantee: No. of Shares: Grant Date: Pursuant to the ZOLL Medical Corporation Amended and Restated 2006 Non-Employee Director Stock Option Plan (the “Plan”), as amended through the date he
February 2, 2012	10-Q	Quarterly Report - FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
January 19, 2012	EX-99.1	ZOLL Medical Corporation Announces First Quarter Results Record First Quarter Revenue and Net Income Exhibit 99.1 ZOLL Medical Corporation Announces First Quarter Results Record First Quarter Revenue and Net Income CHELMSFORD, Mass.-(BUSINESS WIRE)-January 19, 2012-ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of resuscitation devices and related software solutions, today announced that revenues for the first quarter of fiscal 2012 increased 18% to $133.7 million, compared to revenues
January 19, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 19, 2012 ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 000-20225 04-2711626 (State or other jurisdiction of incorporation) (Comm
December 22, 2011	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confide
December 22, 2011	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confide
December 22, 2011	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 d273380d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 18, 2011 ZOLL MEDICAL CORPORATION (Exact Name of Registrant as Specified in Charter) Massachusetts 000-20225 04-2711626 (State or Other Jurisdic
December 1, 2011	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) 10-K/A 1 d221219d10ka.htm FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED OCTOBER 2, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD
November 23, 2011	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K 10-K 1 d221219d10k.htm FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED OCTOBER 2, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO
November 23, 2011	EX-21.1	LIST OF SUBSIDIARIES EX-21.1 2 d221219dex211.htm SUBSIDIARIES OF THE COMPANY Exhibit 21.1 LIST OF SUBSIDIARIES Bio-Detek, Incorporated, incorporated in Massachusetts. ZOLL Medical (U.K.) Ltd, incorporated in United Kingdom. ZOLL Medical Deutschland (GmbH), incorporated in Germany. ZOLL Medical Canada, Inc., incorporated in Canada. ZOLL Data Systems, Inc., incorporated in Delaware. ZOLL Medical France SNC, established
November 17, 2011	EX-99.1	CORRECTING and REPLACING ZOLL Medical Corporation Announces Record Q4 and Annual Results Exhibit 99.1 CORRECTING and REPLACING ZOLL Medical Corporation Announces Record Q4 and Annual Results CHELMSFORD, Mass.-(BUSINESS WIRE)-November 16, 2011-In the second and fourth paragraphs of release dated November 16, 2011, customer and geographic sales detail has been corrected. The corrected release reads: ZOLL MEDICAL CORPORATION ANNOUNCES RECORD Q4 AND ANNUAL RESULTS ~Record Annual Revenues
November 17, 2011	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 16, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 16, 2011 ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 000-20225 04-2711626 (State or other jurisdiction o
November 16, 2011	EX-99.1	ZOLL Medical Corporation Announces Record Q4 and Annual Results - Record Annual Revenues Exceeding $520M - - Record Annual EPS of $1.39 Grows 60% - - Record Q4 Revenue of $152M Grows 26% - - Record Q4 EPS of $0.52 Grows 58% - EX-99.1 2 a50076366ex991.htm EXHIBIT 99.1 Exhibit 99.1 ZOLL Medical Corporation Announces Record Q4 and Annual Results - Record Annual Revenues Exceeding $520M - - Record Annual EPS of $1.39 Grows 60% - - Record Q4 Revenue of $152M Grows 26% - - Record Q4 EPS of $0.52 Grows 58% - CHELMSFORD, Mass.-(BUSINESS WIRE)-November 16, 2011-ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resus
November 16, 2011	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 16, 2011 ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 000-20225 04-2711626 (State or other jurisdiction of incorporation) (Com
October 11, 2011	SC 13G/A	SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Zoll Medical Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 989922109 (CUSIP Number) September 30, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th
August 24, 2011	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 3, 2011. or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-20225 ZO
August 8, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 3, 2011. or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-20225 ZOLL
July 28, 2011	EX-99.1	ZOLL Medical Corporation Announces Third Quarter Results ~ Record Quarterly Revenue, Net Income and Backlog ~ EX-99.1 2 a6811225ex991.htm EXHIBIT 99.1 Exhibit 99.1 ZOLL Medical Corporation Announces Third Quarter Results ~ Record Quarterly Revenue, Net Income and Backlog ~ CHELMSFORD, Mass.-(BUSINESS WIRE)-July 28, 2011-ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, today announced that revenues for the third quarter of fiscal 2011 incre
July 28, 2011	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 28, 2011 ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 000-20225 04-2711626 (State or other jurisdiction of incorporation) (Commiss
May 12, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 28, 2011	EX-99.1	ZOLL Medical Corporation Announces Second Quarter Results ~ Record Second Quarter Revenue and Net Income ~ Exhibit 99.1 ZOLL Medical Corporation Announces Second Quarter Results ~ Record Second Quarter Revenue and Net Income ~ CHELMSFORD, Mass.-(BUSINESS WIRE)-April 28, 2011-ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, today announced that revenues for the second quarter of fiscal 2011 increased 14% to $122.5 million, compared to re
April 28, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 28, 2011 ZOLL MEDICAL CORPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 28, 2011 ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 000-20225 04-2711626 (State or other jurisdiction of incorporation) (Commis
April 28, 2011	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 10, Amendment No. 1 to Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 10, 2011 ZOLL MEDICAL CORPORATION (Exact Name of Registrant as Specified in Charter) Massachusetts 000-20225 04-2711626 (State
March 24, 2011	S-8	As filed with the Securities and Exchange Commission on March 24, 2011 Form S-8 As filed with the Securities and Exchange Commission on March 24, 2011 Registration No.
February 15, 2011	EX-10.1	ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2001 STOCK INCENTIVE PLAN Amended and Restated 2001 Stock Incentive Plan Exhibit 10.1 ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2001 STOCK INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the ZOLL Medical Corporation Amended and Restated 2001 Stock Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees and other key persons (incl
February 15, 2011	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 10, 2011 ZOLL MEDICAL CORPORATION (Exact Name of Registrant as Specified in Charter) Massachusetts 000-20225 04-2711626 (State or Other Jurisdiction of Incorporation) (Commis
February 15, 2011	EX-10.2	ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2006 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN EX-10.2 3 dex102.htm AMENDED AND RESTATED 2006 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN Exhibit 10.2 ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2006 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the ZOLL Medical Corporation Amended and Restated 2006 Non-Employee Director Stock Option Plan (the “Plan”). The purpose of the Plan
February 10, 2011	SC 13G/A	SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Zoll Medical Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 989922109 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi
February 9, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 9, 2011	SC 13G/A	SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) ZOLL MEDICAL CORP - - (Name of Issuer) Common Stock - - (Title of Class of Securities) 989922109 - - (CUSIP Number) December 31, 2010 - - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche
January 31, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 26, 2011 ZOLL MEDICAL COR Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 26, 2011 ZOLL MEDICAL CORPORATION (Exact Name of Registrant as Specified in Charter) Massachusetts 000-20225 04-2711626 (State or Other Jurisdiction of Incorporation)
January 31, 2011	EX-3.1	CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED BY-LAWS OF ZOLL MEDICAL CORPORATION Certificate of Amendment to the Company's Amended and Restated By-Laws Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED BY-LAWS OF ZOLL MEDICAL CORPORATION The undersigned, being the Secretary of ZOLL Medical Corporation, a Massachusetts corporation (the “Corporation”), hereby certifies that the Board of Directors of the Corporation approved the following amendments to the Amended
January 27, 2011	EX-99.1	ZOLL Medical Corporation Announces First Quarter Results ~ Record First Quarter Revenue and Earnings ~ EX-99.1 2 a6588805ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ZOLL Medical Corporation Announces First Quarter Results ~ Record First Quarter Revenue and Earnings ~ CHELMSFORD, Mass.-(BUSINESS WIRE)-January 27, 2011-ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, today announced that revenues for the first quarter of fiscal 2011 increase
January 27, 2011	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 27, 2011 ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 000-20225 04-2711626 (State or other jurisdiction of incorporation) (Comm
December 23, 2010	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame Definitive Notice and Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
December 23, 2010	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide
December 23, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 23, 2010 ZOLL MEDICAL CO Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 23, 2010 ZOLL MEDICAL CORPORATION (Exact Name of Registrant as Specified in Charter) Massachusetts 000-20225 04-2711626 (State or Other Jurisdiction of Incorporation
December 17, 2010	EX-21.1	LIST OF SUBSIDIARIES Exhibit 21.1 LIST OF SUBSIDIARIES Bio-Detek, Incorporated, incorporated in Massachusetts. ZOLL Medical (U.K.) Ltd, incorporated in United Kingdom. ZOLL Medical Deutschland (GmbH), incorporated in Germany. ZOLL Medical Canada, Inc., incorporated in Canada. ZOLL Data Systems, Inc., incorporated in Delaware. ZOLL Medical France SNC, established in France. ZOLL Medical Australia, Pty. Limited, incorpo
December 17, 2010	EX-10.45	ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2001 STOCK INCENTIVE PLAN Amended & Restated 2001 Stock Incentive Plan Exhibit 10.45 ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2001 STOCK INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the ZOLL Medical Corporation Amended and Restated 2001 Stock Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees and other key persons (inclu
December 17, 2010	EX-10.46	ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2006 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN EX-10.46 3 dex1046.htm AMENDED & RESTATED 2006 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN Exhibit 10.46 ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2006 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the ZOLL Medical Corporation Amended and Restated 2006 Non-Employee Director Stock Option Plan (the “Plan”). The purpose of the Plan
December 17, 2010	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED OCTOBER 3, 2010 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . COMMISSION FILE NUMBER 0-20225
November 18, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 18, 2010 Date of Report (Date of earliest event reported) ZOLL MEDICAL COR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 18, 2010 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 0-20225 04-2711626 (State or other jurisdiction of incorporation) (Commi
November 18, 2010	EX-99.1	ZOLL Medical Corporation Announces Annual Results ~Record Annual Revenues ~ Exhibit 99.1 ZOLL Medical Corporation Announces Annual Results ~Record Annual Revenues ~ CHELMSFORD, Mass.-(BUSINESS WIRE)-November 18, 2010-ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of resuscitation devices and related software solutions, today announced that fiscal 2010 revenues were $444.0 million, compared to fiscal 2009 revenues of $385.2 million, an increase of 15%. Revenue r
August 11, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 4, 2010. or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-20225 ZOLL
July 29, 2010	EX-99.1	ZOLL Medical Corporation Announces Third Quarter Results ~Profits Rebound on Record Third Quarter Revenues ~ EX-99.1 2 a6377702ex991.htm EXHIBIT 99.1 Exhibit 99.1 ZOLL Medical Corporation Announces Third Quarter Results ~Profits Rebound on Record Third Quarter Revenues ~ CHELMSFORD, Mass.-(BUSINESS WIRE)-July 29, 2010-ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced that revenues for the third quarter of fiscal 2010 increased 17%
July 29, 2010	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a6377702.htm ZOLL MEDICAL CORP. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 29, 2010 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 0-20225 04-2711626 (State or other
May 14, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 4, 2010. or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-20225 ZOL
April 29, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 29, 2010 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 29, 2010 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 0-20225 04-2711626 (State or other jurisdiction of incorporation) (Commissi
April 29, 2010	EX-99.1	ZOLL Medical Corporation Announces Second Quarter Results ~Record Second Quarter Revenues Achieved~ Exhibit 99.1 ZOLL Medical Corporation Announces Second Quarter Results ~Record Second Quarter Revenues Achieved~ CHELMSFORD, Mass.-(BUSINESS WIRE)-April 29, 2010-ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced that revenues for the second quarter of fiscal 2010 increased 15% to $107.1 million, compared to revenues in the se
March 10, 2010	LETTER	LETTER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Mail Stop 3030 March 10, 2010 Via U.S. Mail Mr. Richard A. Packer Chief Executive Officer ZOLL Medical Corporation 269 Mill Road Chelmsford, MA 01824 Re: ZOLL Medical Corporation Form 10-K for fiscal year ended September 27, 2009 Filed December 10, 2009 File No. 0-20225 Dear Mr. Packer: We have completed our review of your For
March 4, 2010	CORRESP	(ZOLL Letterhead) Correspondence (ZOLL Letterhead) March 4, 2010 Via EDGAR and Federal Express Mr. Kevin L. Vaughn, Accounting Branch Chief Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: ZOLL Medical Corporation Form 10-K for fiscal year ended September 27, 2009 Filed December 10, 2009 File No. 0-20225 Dear Mr. Vaughn: This letter is in
February 22, 2010	LETTER	LETTER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Mail Stop 3030 February 22, 2010 Via Facsimile and U.S. Mail Mr. Richard A. Packer Chief Executive Officer ZOLL Medical Corporation 269 Mill Road Chelmsford, MA 01824 Re: ZOLL Medical Corporation Form 10-K for fiscal year ended September 27, 2009 Filed December 10, 2009 File No. 0-20225 Dear Mr. Packer: We have reviewed your f
February 12, 2010	SC 13G/A	13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* ZOLL MEDICAL CORPORATION - - (Name of Issuer) Common Stock - - (Title of Class of Securities) 989922109 - - (CUSIP Number) December 31, 2009 - - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu
February 11, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 3, 2010. or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-20225 Z
February 10, 2010	SC 13G/A	SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Zoll Medical Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 989922109 (CUSIP Number) December 31, 2009 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche
February 8, 2010	SC 13G/A	SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) ZOLL MEDICAL CORP - - (Name of Issuer) Common Stock - - (Title of Class of Securities) 989922109 - - (CUSIP Number) January 29, 2010 - - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched
January 29, 2010	SC 13G/A	SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) ZOLL MEDICAL CORP - - (Name of Issuer) Common Stock - - (Title of Class of Securities) 989922109 - - (CUSIP Number) December 31, 2009 - - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche
January 28, 2010	EX-99.1	ZOLL Medical Corporation Announces First Quarter Results Revenue Growth Accelerating Exhibit 99.1 ZOLL Medical Corporation Announces First Quarter Results Revenue Growth Accelerating CHELMSFORD, Mass.-(BUSINESS WIRE)-January 28, 2010-ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced that revenues for the first quarter of fiscal 2010 increased 18% to $105,212,000, compared to revenues in the first quarter of l
January 28, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 28, 2010 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 28, 2010 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 0-20225 04-2711626 (State or other jurisdiction of incorporation) (Commis
December 22, 2009	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
December 22, 2009	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
December 10, 2009	SC 13G/A	ZOLL MEDICAL SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
December 10, 2009	EX-21.1	LIST OF SUBSIDIARIES Subsidiaries of the Company Exhibit 21.1 LIST OF SUBSIDIARIES Bio-Detek, Incorporated, incorporated in Massachusetts. ZOLL Medical (U.K.) Ltd, incorporated in United Kingdom. ZOLL Medical Deutschland (GmbH), incorporated in Germany. ZOLL Medical Canada, Inc., incorporated in Canada. ZOLL Data Systems, Inc., incorporated in Delaware. ZOLL Medical France SNC, established in France. ZOLL Medical Aust
December 10, 2009	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED SEPTEMBER 27, 2009 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . COMMISSION FILE NUMBER 0-20
November 10, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 10, 2009 Date of Report (Date of earliest event reported) ZOLL MEDICAL COR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 10, 2009 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 0-20225 04-2711626 (State or other jurisdiction of incorporation) (Commi
November 10, 2009	EX-99.1	ZOLL Medical Corporation Announces Annual Results Record Fourth Quarter Revenues Exhibit 99.1 ZOLL Medical Corporation Announces Annual Results Record Fourth Quarter Revenues CHELMSFORD, Mass.-(BUSINESS WIRE)-November 10, 2009-ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced that fiscal 2009 revenues were $385.2 million, compared to fiscal 2008 revenues of $398.0 million, a decline of 3%. Revenue results
August 7, 2009	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 23, 2009	EX-99.1	ZOLL Medical Corporation Announces Third Quarter Results Business Conditions Remain Unchanged Exhibit 99.1 ZOLL Medical Corporation Announces Third Quarter Results Business Conditions Remain Unchanged CHELMSFORD, Mass.-(BUSINESS WIRE)-July 23, 2009-ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced that revenues for the third quarter of fiscal 2009 were $95,147,000, compared to revenues in the third quarter of last ye
July 23, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 23, 2009 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPORA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 23, 2009 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 0-20225 04-2711626 (State or other jurisdiction of incorporation) (Commissio
July 22, 2009	POS AM	As filed with the Securities and Exchange Commission on July 22, 2009 As filed with the Securities and Exchange Commission on July 22, 2009 Registration Statement No.
July 16, 2009	8-K/A	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 4, 2009 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts (State or other jurisdiction of incorporation) 0-20225 (Co
July 16, 2009	EX-99.1	UNAUDITED PRO FORMA COMBINED CONDENSED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA COMBINED CONDENSED FINANCIAL INFORMATION On May 4, 2009, ZOLL Medical Corporation (the “Company” or “ZOLL”) completed the acquisition of substantially all the assets of the intravascular temperature management business of Alsius Corporation (“Alsius”) pursuant to an Asset Purchase Agreement (the “Agreement”) by and among ZOLL Circulation, Inc., a wholly-owned subsi
May 8, 2009	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 29, 2009. or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-20225 ZO
May 7, 2009	8-K	Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 4, 2009 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 0-20225 04-2711626 (State or other jurisdiction of incorporation) (Commission
April 22, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 22, 2009 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 22, 2009 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 0-20225 04-2711626 (State or other jurisdiction of incorporation) (Commissi
April 22, 2009	EX-99.1	ZOLL Medical Corporation Announces Second Quarter Results Results in Line with Previous Announcement Exhibit 99.1 ZOLL Medical Corporation Announces Second Quarter Results Results in Line with Previous Announcement CHELMSFORD, Mass.-(BUSINESS WIRE)-April 22, 2009-ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced that revenues for the second quarter of fiscal 2009 were $92,708,000, compared to revenues in the second quarter
April 22, 2009	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits 8-K 1 d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 21, 2009 ZOLL MEDICAL CORPORATION (Exact Name of Registrant as Specified in Charter) Massachusetts 000-20225 04-2711626 (State or Other Jurisdiction of In
April 22, 2009	EX-3.1	CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED BY-LAWS OF ZOLL MEDICAL CORPORATION EX-3.1 2 dex31.htm CERTIFICATE OF AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED BY-LAWS Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED BY-LAWS OF ZOLL MEDICAL CORPORATION The undersigned, being the Secretary of ZOLL Medical Corporation, a Massachusetts corporation (the “Corporation”), hereby certifies that the Board of Directors of the Corporation approved the following amendme
April 9, 2009	SC 13G/A	DOC ONE SCHEDULE 13G Amendment No. 4 Zoll Medical Corporation Common Stock Cusip #989922109 Cusip #989922109 Item 1: Reporting Person - FMR LLC Item 4: Delaware Item 5: 191,330 Item 6: 0 Item 7: 363,889 Item 8: 0 Item 9: 363,889 Item 11: 1.726% Item 12: HC Cusip #989922109 Item 1: Reporting Person - Edward C. Johnson 3d Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 363,889 Item 8: 0 Item 9:
March 31, 2009	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 31, 2009 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 0-20225 04-2711626 (State or other jurisdiction of incorporation) (Commissi
March 31, 2009	EX-99.1	ZOLL Medical Corporation Announces Preliminary Second Quarter Results Exhibit 99.1 ZOLL Medical Corporation Announces Preliminary Second Quarter Results CHELMSFORD, Mass.-(BUSINESS WIRE)-March 31, 2009-ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced that preliminary revenues for the second quarter were approximately $90 - $92 million, down approximately 8% from revenues in the same period la
February 17, 2009	SC 13G/A	DOC ONE SCHEDULE 13G Amendment No. 3 Zoll Medical Corporation Common Stock Cusip #989922109 Cusip #989922109 Item 1: Reporting Person - FMR LLC Item 4: Delaware Item 5: 625,253 Item 6: 0 Item 7: 2,099,319 Item 8: 0 Item 9: 2,099,319 Item 11: 9.968% Item 12: HC Cusip #989922109 Item 1: Reporting Person - Edward C. Johnson 3d Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 2,099,319 Item 8: 0 I
February 17, 2009	SC 13G/A	SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Zoll Medical Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 989922109 (CUSIP Number) December 31, 2008 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche
February 17, 2009	SC 13G/A	ZOLL MEDICAL CORPORATION SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 - SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No.2)* ZOLL MEDICAL CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 989922109 (CUSIP Number) December 31, 2008 (Da
February 13, 2009	EX-24	EX-24 EXHIBIT I JOINT FILING AGREEMENT - Each of the undersigned hereby agrees that the Schedule 13G filed herewith is filed jointly, pursuant to Rule 13d-1(f)(1) of the Securities Exchange Act of 1934, as amended on behalf of each of them.
February 13, 2009	SC 13G/A	SC 13G/A Page 1 of 11 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
February 13, 2009	SC 13G/A	SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ZOLL MEDICAL CORPORATION - - (Name of Issuer) common stock - - (Title of Class of Securities) 989922109 - - (CUSIP Number) December 31, 2008 - - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu
February 12, 2009	S-8	As filed with the Securities and Exchange Commission on February 12, 2009 As filed with the Securities and Exchange Commission on February 12, 2009 Registration No.
February 10, 2009	SC 13G/A	ZOLL MEDICAL CORP SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
February 6, 2009	EX-10.1	ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2001 STOCK INCENTIVE PLAN Amended and Restated 2001 Stock Incentive Plan Exhibit 10.1 ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2001 STOCK INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the ZOLL Medical Corporation Amended and Restated 2001 Stock Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees and other key persons (incl
February 6, 2009	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended December 28, 2008. Or ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission file number 0-202
February 6, 2009	EX-10.2	ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2006 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN EX-10.2 3 dex102.htm AMENDED AND RESTATED 2006 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN Exhibit 10.2 ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2006 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the ZOLL Medical Corporation Amended and Restated 2006 Non-Employee Director Stock Option Plan (the “Plan”). The purpose of the Plan
February 5, 2009	SC 13G	SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (New) ZOLL MEDICAL CORP (Name of Issuer) Common Stock (Title of Class of Securities) 989922109 (CUSIP Number) December 31, 2008 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-
January 22, 2009	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 22, 2009 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 0-20225 04-2711626 (State or other jurisdiction of incorporation) (Commis
January 22, 2009	EX-99.1	ZOLL Medical Corporation Announces First Quarter Results Significant Growth Achieved in New Product Areas Exhibit 99.1 ZOLL Medical Corporation Announces First Quarter Results Significant Growth Achieved in New Product Areas CHELMSFORD, Mass.-(BUSINESS WIRE)-January 22, 2009-ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced that revenues for the first quarter of fiscal 2009 were $89,462,000, compared to revenues in the first qua
December 18, 2008	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide
December 8, 2008	EX-10.33	ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2006 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN EX-10.33 5 dex1033.htm AMENDED & RESTATED 2006 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN Exhibit 10.33 ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2006 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the ZOLL Medical Corporation Amended and Restated 2006 Non-Employee Director Stock Option Plan (the “Plan”). The purpose of the Plan
December 8, 2008	EX-21.1	LIST OF SUBSIDIARIES Exhibit 21.1 LIST OF SUBSIDIARIES Bio-Detek, Incorporated, incorporated in Massachusetts. ZOLL Medical (U.K.) Ltd, incorporated in United Kingdom. ZOLL Medical Deutschland (GmbH), incorporated in Germany. ZOLL Medical Canada, Inc., incorporated in Canada. ZOLL Data Systems, Inc., incorporated in Delaware. ZOLL Medical France SNC, established in France. ZOLL Medical Australia, Pty. Limited, incorpo
December 8, 2008	EX-10.40	AMENDMENT TO EXECUTIVE SEVERANCE AGREEMENT EX-10.40 11 dex1040.htm AMENDMENT DATED NOVEMBER 19, 2008 TO EXECUTIVE SEVERANCE AGREEMENT Exhibit 10.40 AMENDMENT TO EXECUTIVE SEVERANCE AGREEMENT This AMENDMENT TO EXECUTIVE SEVERANCE AGREEMENT, dated November 19, 2008, is by and between ZOLL MEDICAL CORPORATION, a Massachusetts corporation (the “Company”), and Donald Boucher (the “Executive”). WHEREAS, the Company and the Executive entered into
December 8, 2008	EX-10.34	NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2006 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN Form of Non-Qualified Stock Option Agreement Exhibit 10.34 NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2006 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ Grant Date: Expiration Date: Pursuant to the ZOLL Medical Corporation Amended and Restated 2006 Non-Employee Director Stock Opti
December 8, 2008	EX-10.31	NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2001 STOCK INCENTIVE PLAN EX-10.31 3 dex1031.htm FORM OF NON-QUALIFIED STOCK OPTION AGREEMENT Exhibit 10.31 NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2001 STOCK INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: $ Grant Date: Expiration Date: Pursuant to the ZOLL Medical Corporation Amended and Restated 2001 Stock Incentive Plan as amen
December 8, 2008	EX-10.43	EXECUTIVE SEVERANCE AGREEMENT EX-10.43 14 dex1043.htm EXECUTIVE SEVERANCE AGREEMENT DATED NOVEMBER 11, 2008 Exhibit 10.43 EXECUTIVE SEVERANCE AGREEMENT AGREEMENT made as of this 11th day of November, 2008 by and between ZOLL Medical Corporation, a Massachusetts corporation with its principal place of business in Chelmsford, Massachusetts (the “Company”), and Jonathan Rennert of Concord, Massachusetts (the “Executive”). 1. Purp
December 8, 2008	EX-10.44	EXECUTIVE SEVERANCE AGREEMENT Executive Severance Agreement dated November 11, 2008 Exhibit 10.44 EXECUTIVE SEVERANCE AGREEMENT AGREEMENT made as of this 11th day of November, 2008 by and between ZOLL Medical Corporation, a Massachusetts corporation with its principal place of business in Chelmsford, Massachusetts (the “Company”), and E. Jane Wilson of Hingham, Massachusetts (the “Executive”). 1. Purpose. The Company considers
December 8, 2008	EX-10.30	ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2001 STOCK INCENTIVE PLAN Amended & Restated 2001 Stock Incentive Plan Exhibit 10.30 ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2001 STOCK INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the ZOLL Medical Corporation Amended and Restated 2001 Stock Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees and other key persons (inclu
December 8, 2008	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED SEPTEMBER 28, 2008 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . COMMISSION FILE NUMBER 0-20
December 8, 2008	EX-10.32	RESTRICTED STOCK AWARD AGREEMENT UNDER THE ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2001 STOCK INCENTIVE PLAN Form of Restricted Stock Award Agreement Exhibit 10.32 RESTRICTED STOCK AWARD AGREEMENT UNDER THE ZOLL MEDICAL CORPORATION AMENDED AND RESTATED 2001 STOCK INCENTIVE PLAN Name of Grantee: No. of Shares: Grant Date: Final Acceptance Date: Pursuant to the ZOLL Medical Corporation Amended and Restated 2001 Stock Incentive Plan (the “Plan”) as amended through the date hereof, ZOLL Medical Corporation (
December 8, 2008	EX-10.37	AMENDMENT TO AMENDED AND RESTATED EXECUTIVE SEVERANCE AGREEMENT EX-10.37 9 dex1037.htm AMENDMENT DATED NOVEMBER 11, 2008 TO AMENDED & RESTATED EXECUTIVE SEVERANCE Exhibit 10.37 AMENDMENT TO AMENDED AND RESTATED EXECUTIVE SEVERANCE AGREEMENT This AMENDMENT TO AMENDED AND RESTATED EXECUTIVE SEVERANCE AGREEMENT, dated November 11, 2008, is by and between ZOLL MEDICAL CORPORATION, a Massachusetts corporation (the “Company”), and A. Ernest Whiton (the “Executive”).
December 8, 2008	EX-10.39	AMENDMENT TO EXECUTIVE SEVERANCE AGREEMENT Amendment dated November 25, 2008 to Executive Severance Agreement Exhibit 10.39 AMENDMENT TO EXECUTIVE SEVERANCE AGREEMENT This AMENDMENT TO EXECUTIVE SEVERANCE AGREEMENT, dated November 25, 2008, is by and between ZOLL MEDICAL CORPORATION, a Massachusetts corporation (the “Company”), and Edward Dunn (the “Executive”). WHEREAS, the Company and the Executive entered into an executive severance agr
December 8, 2008	EX-10.41	AMENDMENT TO EXECUTIVE SEVERANCE AGREEMENT Exhibit 10.41 AMENDMENT TO EXECUTIVE SEVERANCE AGREEMENT This AMENDMENT TO EXECUTIVE SEVERANCE AGREEMENT, dated November 25, 2008, is by and between ZOLL MEDICAL CORPORATION, a Massachusetts corporation (the ?Company?), and Ward Hamilton (the ?Executive?). WHEREAS, the Company and the Executive entered into an executive severance agreement effective as of May 7, 2002 (the ?Agreement?); and WHEREAS
December 8, 2008	EX-10.45	AMENDMENT TO EXECUTIVE SEVERANCE AGREEMENT Amendment dated November 11, 2008 to Executive Severance Agreement Exhibit 10.45 AMENDMENT TO EXECUTIVE SEVERANCE AGREEMENT This AMENDMENT TO EXECUTIVE SEVERANCE AGREEMENT, dated November 11, 2008, is by and between ZOLL MEDICAL CORPORATION, a Massachusetts corporation (the “Company”), and Alexander Moghadam (the “Executive”). WHEREAS, the Company and the Executive entered into an executive severa
December 8, 2008	EX-10.42	AMENDMENT TO EXECUTIVE SEVERANCE AGREEMENT EX-10.42 13 dex1042.htm AMENDMENT DATED DECEMBER 1, 2008 TO EXECUTIVE SEVERANCE AGREEMENT Exhibit 10.42 AMENDMENT TO EXECUTIVE SEVERANCE AGREEMENT This AMENDMENT TO EXECUTIVE SEVERANCE AGREEMENT, dated December 1, 2008, is by and between ZOLL MEDICAL CORPORATION, a Massachusetts corporation (the “Company”), and Steven Flora (the “Executive”). WHEREAS, the Company and the Executive entered into an
December 8, 2008	EX-10.35	AMENDMENT TO EMPLOYMENT AGREEMENT Amendment dated November 17, 2008 to Employee Agreement Exhibit 10.35 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT, dated November 17, 2008, is by and between ZOLL MEDICAL CORPORATION, a Massachusetts corporation (the “Company”), and Richard A. Packer (the “Executive”). WHEREAS, the Company and the Executive entered into an employment agreement effective as of July 19,
December 8, 2008	EX-10.36	AMENDMENT TO SENIOR EXECUTIVE SEVERANCE AGREEMENT EX-10.36 8 dex1036.htm AMENDMENT DATED NOVEMBER 17, 2008 TO SENIOR EXECUTIVE SEVERANCE AGREEMENT Exhibit 10.36 AMENDMENT TO SENIOR EXECUTIVE SEVERANCE AGREEMENT This AMENDMENT TO SENIOR EXECUTIVE SEVERANCE AGREEMENT, dated November 17, 2008, is by and between ZOLL MEDICAL CORPORATION, a Massachusetts corporation (the “Company”), and Richard A. Packer (the “Executive”). WHEREAS, the Company and the
November 13, 2008	EX-99.1	ZOLL Medical Corporation Announces Record Annual Results Record Revenues and Profits for Fourth Quarter Exhibit 99.1 ZOLL Medical Corporation Announces Record Annual Results Record Revenues and Profits for Fourth Quarter CHELMSFORD, Mass.-(BUSINESS WIRE)-November 13, 2008-ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced that fiscal 2008 revenues increased 29% to $398,018,000, compared to fiscal 2007 revenues of $309,451,000.
November 13, 2008	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 13, 2008 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 0-20225 04-2711626 (State or other jurisdiction of incorporation) (Commi
November 12, 2008	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2008 ZOLL MEDICAL CORP Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2008 ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in charter) Massachusetts 000-20225 04-2711626 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.
November 12, 2008	EX-3.1	CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED BY-LAWS OF ZOLL MEDICAL CORPORATION Certificate of Amendment EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED BY-LAWS OF ZOLL MEDICAL CORPORATION The undersigned, being the Secretary of ZOLL Medical Corporation., a Massachusetts corporation (the “Corporation”), hereby certifies that the Board of Directors of the Corporation approved the following amendments to the Amended and Restated By-Laws (the “By-laws”) of the C
October 10, 2008	SC 13G	SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Zoll Medical Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 989922109 (CUSIP Number) September 30, 2008 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche
September 10, 2008	SC 13G/A	DOC ONE SCHEDULE 13G Amendment No. 2 Zoll Medical Corporation Common Stock Cusip #989922109 Cusip #989922109 Item 1: Reporting Person - FMR LLC Item 4: Delaware Item 5: 654,987 Item 6: 0 Item 7: 2,064,154 Item 8: 0 Item 9: 2,064,154 Item 11: 9.814% Item 12: HC Cusip #989922109 Item 1: Reporting Person - Edward C. Johnson 3d Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 2,064,154 Item 8: 0 I
August 19, 2008	LETTER	LETTER August 19, 2008 Mail Stop 6010 Stephen Korn Vice President and General Counsel Zoll Medical Corporation 269 Mill Road Chelmsford, MA 01824 Re: Zoll Medical Corporation Annual Report on Form 10-K Filed December 13, 2007 File No.
August 8, 2008	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 30, 2008	CORRESP	[ON ZOLL MEDICAL CORPORATION LETTERHEAD] [ON ZOLL MEDICAL CORPORATION LETTERHEAD] July 30, 2008 Via EDGAR and Federal Express Mr.
July 24, 2008	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 July 24, 2008 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 July 24, 2008 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 0-20225 04-2711626 (State or other jurisdiction of incorporation) (Commissi
July 24, 2008	EX-99.1	ZOLL Medical Corporation Announces Record Third Quarter Results Q3 Revenue Exceeds $100M; Earnings Increase 33% Exhibit 99.1 ZOLL Medical Corporation Announces Record Third Quarter Results Q3 Revenue Exceeds $100M; Earnings Increase 33% CHELMSFORD, Mass.-(BUSINESS WIRE)-ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced revenues for the third quarter of fiscal 2008 of $100,244,000, an increase of 27% compared to revenues in the third qu
July 9, 2008	LETTER	LETTER
July 1, 2008	EX-99.1	ZOLL MEDICAL CORPORATION ANNOUNCES THE ADDITION OF A PRESIDENT Two Executives Named as ZOLL’s First Senior Vice Presidents EXHIBIT 99.1 ZOLL MEDICAL CORPORATION ANNOUNCES THE ADDITION OF A PRESIDENT Two Executives Named as ZOLL?s First Senior Vice Presidents June 30, 2008?CHELMSFORD, MA.?ZOLL Medical Corporation (Nasdaq: GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, announced that Jonathan Rennert, 44, today joined ZOLL to serve as its President and will be primarily responsible fo
July 1, 2008	EX-10.1	June 10, 2008 Offer Letter for Mr. Rennert EXHIBIT 10.1 June 10, 2008 Mr. Jonathan Rennert 39 Revolutionary Road Concord, MA 01742 Dear Jonathan: It is with great pleasure that I extend this offer to you, to join ZOLL Medical Corporation as the President, reporting directly to me. Your start date will be on a day that has been mutually agreed upon. In your role as President, you will be compensated at a rate of
July 1, 2008	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 30, 2008 ZOLL MEDICAL CORPORA Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 30, 2008 ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in charter) Massachusetts 000-20225 04-2711626 (State or other jurisdiction of incorporation) (Co
June 26, 2008	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK REPURCHASE SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Form 11-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK REPURCHASE SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 þ Annual Report pursuant to Section 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2007 ¨ Transition Report pursuant to Section 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-20225 ZOLL Medical Corporation Employee Savings Plan ZOLL Medical Corporation 269 Mill Road Chelmsford, Massachusetts 01824-4105 Table of Contents REQUIRED INFORMATION ATTACHED 1.
June 26, 2008	EX-99.1	ZOLL MEDICAL APPOINTS NEW INDEPENDENT AUDITORS EXHIBIT 99.1 INVESTOR CONTACT: A. Ernest Whiton Chief Financial Officer ZOLL Medical Corporation +1 (978) 421-9655 FOR IMMEDIATE RELEASE ZOLL MEDICAL APPOINTS NEW INDEPENDENT AUDITORS CHELMSFORD, MASS., June 23, 2008?ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of resuscitation devices and related software solutions, announced today that its Audit Committee had acted to change ZOLL?s
June 26, 2008	CORRESP	[ON ZOLL MEDICAL CORPORATION LETTERHEAD] SEC Response Letter [ON ZOLL MEDICAL CORPORATION LETTERHEAD] June 26, 2008 Via EDGAR and Federal Express Mr.
June 26, 2008	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 23, 2008 ZOLL MEDICAL CORPORA Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 23, 2008 ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in charter) Massachusetts 000-20225 04-2711626 (State or other jurisdiction of incorporation) (Co
June 26, 2008	EX-16.1	June 24, 2008 Letter from Ernst & Young LLP EXHIBIT 16.1 June 24, 2008 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Gentlemen: We have read Item 4.01 of Form 8-K with a date of report of June 23, 2008, of ZOLL Medical Corporation and are in agreement with the statements contained in the first three paragraphs therein. We have no basis to agree or disagree with other statements of t
June 10, 2008	LETTER	LETTER
May 9, 2008	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended March 30, 2008. Or ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission file number 0-20225
April 24, 2008	EX-3.1	RESOLUTION OF DIRECTORS ESTABLISHING SERIES A JUNIOR PARTICIPATING CUMULATIVE PREFERRED STOCK ZOLL MEDICAL CORPORATION EX-3.1 2 dex31.htm AMENDED AND RESTATED CERTIFICATE OF VOTE OF DIRECTORS ESTABLISHING Exhibit 3.1 RESOLUTION OF DIRECTORS ESTABLISHING SERIES A JUNIOR PARTICIPATING CUMULATIVE PREFERRED STOCK of ZOLL MEDICAL CORPORATION Pursuant to Section 6.02 of Chapter 156D of the General Laws of The Commonwealth of Massachusetts: RESOLVED, that pursuant to authority conferred upon and vested in the Board of Di
April 24, 2008	EX-99.1	ZOLL Medical Corporation Renews Shareholder Rights Plan Exhibit 99.1 For further information contact: A. Ernest Whiton Chief Financial Officer ZOLL Medical Corporation 978-421-9655 FOR IMMEDIATE RELEASE ZOLL Medical Corporation Renews Shareholder Rights Plan Chelmsford, MA, April 23, 2008 – ZOLL Medical Corporation (NASDAQGS: ZOLL), a manufacturer of resuscitation devices and software solutions, announced today that its Board of Directors has renewed i
April 24, 2008	EX-4.1	ZOLL MEDICAL CORPORATION COMPUTERSHARE TRUST COMPANY, N.A. AS RIGHTS AGENT SHAREHOLDER RIGHTS AGREEMENT DATED AS OF APRIL 23, 2008 TABLE OF CONTENTS Section Page Section 1. Certain Definitions 2 Section 2. Appointment of Rights Agent 7 Section 3. Iss EX-4.1 3 dex41.htm SHAREHOLDER RIGHTS AGREEMENT BETWEEN ZOLL MEDICAL CORP. AND COMPUTERSHARE TRUST Exhibit 4.1 ZOLL MEDICAL CORPORATION AND COMPUTERSHARE TRUST COMPANY, N.A. AS RIGHTS AGENT SHAREHOLDER RIGHTS AGREEMENT DATED AS OF APRIL 23, 2008 TABLE OF CONTENTS Section Page Section 1. Certain Definitions 2 Section 2. Appointment of Rights Agent 7 Section 3. Issue of Right Certificates. 8 Section
April 24, 2008	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 22, 2008 ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in charter) Massachusetts 000-20225 04-2711626 (State or other jurisdiction of incorporation) (Commission
April 24, 2008	8-A12B	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL MEDICAL CORPORATION (Exact name of regis UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in charter) Massachusetts 04-2711626 (State or other jurisdiction of incorporation) (IRS employer identification no.) 269 Mill Road
April 24, 2008	EX-4.2	AMENDMENT NO. 2 SHAREHOLDER RIGHTS AGREEMENT Amendment No. 2 to Shareholder Rights Agreement Exhibit 4.2 AMENDMENT NO. 2 TO SHAREHOLDER RIGHTS AGREEMENT This Amendment No. 2 (the “Amendment”) to the Rights Agreement (as defined below) is entered into as of April 24, 2008, by and between ZOLL Medical Corporation, a Massachusetts corporation (the “Company”), and Computershare Trust Company, N.A. (as successor rights agent to State Street Bank
April 24, 2008	8-A12G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL MEDICAL CORPORATION (Exact name of reg UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in charter) Massachusetts 04-2711626 (State or other jurisdiction of incorporation) (IRS employer identification no.) 269 Mill Ro
April 23, 2008	EX-99.1	ZOLL Medical Corporation Announces Record Second Quarter Results Quarterly Revenue Increases 40%; Quarterly EPS Increases 80% Exhibit 99.1 ZOLL Medical Corporation Announces Record Second Quarter Results Quarterly Revenue Increases 40%; Quarterly EPS Increases 80% CHELMSFORD, Mass.-(BUSINESS WIRE)-ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced revenues for the second quarter of fiscal 2008 of $99,160,000, an increase of 40% compared to revenues i
April 23, 2008	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 April 23, 2008 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 April 23, 2008 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 0-20225 04-2711626 (State or other jurisdiction of incorporation) (Commiss
February 14, 2008	SC 13G	SC 13G Page 1 of 12 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
February 14, 2008	SC 13G/A	DOC ONE SCHEDULE 13G Amendment No. 1 Zoll Medical Corporation Common Stock Cusip #989922109 Cusip #989922109 Item 1: Reporting Person - FMR LLC Item 4: Delaware Item 5: 523,634 Item 6: 0 Item 7: 3,070,458 Item 8: 0 Item 9: 3,070,458 Item 11: 14.987% Item 12: HC Cusip #989922109 Item 1: Reporting Person - Edward C. Johnson 3d Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 3,070,458 Item 8: 0
February 14, 2008	EX-24	EX-24 EXHIBIT I JOINT FILING AGREEMENT - Each of the undersigned hereby agrees that the Schedule 13G filed herewith is filed jointly, pursuant to Rule 13d-1(f)(1) of the Securities Exchange Act of 1934, as amended on behalf of each of them.
February 13, 2008	SC 13G/A	AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Zoll Medical Corporation - - (Name of Issuer) Common Stock, $0.02 par value - - (Title of Class of Securities) 989922109 - - (CUSIP Number) December 31,2007 - - (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate
February 13, 2008	SC 13G/A	ZOLL MEDICAL CORPORATION SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 - SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 1)* Zoll Medical Corporation (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 989922109 (CUSIP Number) December 31, 2007 (D
February 8, 2008	SC 13G	ZOLL MEDICAL SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
February 6, 2008	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ZOLL MEDICAL CORP (Name of Issuer) Common Stock (Title of Class of Securities) 989922109 (CUSIP Number) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ZOLL MEDICAL CORP (Name of Issuer) Common Stock (Title of Class of Securities) 989922109 (CUSIP Number) December 31, 2007 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched
February 5, 2008	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the quarterly period ended December 30, 2007. Or ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission file number 0-202
February 5, 2008	EX-10.1	Summary of Cash Incentive Bonus Plan Summary of Cash Incentive Bonus Plan EXHIBIT 10.1 Summary of Cash Incentive Bonus Plan ZOLL Medical Corporation (the “Company”) maintains a cash incentive bonus plan pursuant to which executives may receive an annual cash bonus, based on their performance as measured against predetermined goals and objectives established by the Compensation Committee and reviewed with the Board of Directors. Speci
February 1, 2008	SC 13G/A	SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ZOLL MEDICAL CORPORATION - - (Name of Issuer) Common Stock , $.01 par value - - (Title of Class of Securities) 989922109 - (CUSIP Number) December 31, 2007 - - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
January 24, 2008	EX-99.1	ZOLL Medical Corporation Announces Record First Quarter Results Defibrillator shipments completed under State of California order Core business sees excellent, broad-based growth Exhibit 99.1 ZOLL Medical Corporation Announces Record First Quarter Results Defibrillator shipments completed under State of California order Core business sees excellent, broad-based growth CHELMSFORD, Mass.-(BUSINESS WIRE)-ZOLL Medical Corporation (NASDAQGS: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced revenues for the first quarter of fiscal 2008 of $9
January 24, 2008	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 January 24, 2008 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 0-20225 04-2711626 (State or other jurisdiction of incorporation) (Commi
January 22, 2008	SC 13G/A	SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (amend) ZOLL MEDICAL CORP (Name of Issuer) Common Stock (Title of Class of Securities) 989922109 (CUSIP Number) December 31, 2007 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13
January 9, 2008	424B3	ZOLL MEDICAL CORPORATION 268,070 Shares of Common Stock 424B3 1 d424b3.htm FORM 424(B)(3) Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-120454 PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus dated February 24, 2007) ZOLL MEDICAL CORPORATION 268,070 Shares of Common Stock This prospectus supplement and the accompanying prospectus (the “base prospectus”) relates to the resale, from time to time, of up to 268,070 shares of our common
December 21, 2007	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Stateme
December 20, 2007	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 14, 2007 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 0-20225 04-2711626 (State or other jurisdiction of incorporation) (Commi
December 13, 2007	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (MARK ONE) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2007 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . COMMISSION FILE NUMBER 0-20
December 13, 2007	EX-21.1	LIST OF SUBSIDIARIES EX-21.1 2 dex211.htm SUBSIDIARIES OF THE COMPANY Exhibit 21.1 LIST OF SUBSIDIARIES Bio-Detek, Incorporated, incorporated in Massachusetts. ZOLL Medical (U.K.) Ltd, incorporated in United Kingdom. ZOLL Medical Deutschland (GmbH), incorporated in Germany. ZOLL Medical Canada, Inc., incorporated in Canada. ZOLL Data Systems, Inc., incorporated in Delaware. ZOLL Medical France NRC, established in Fran
November 15, 2007	8-K	ZOLL MEDICAL CORPORATION, 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 15, 2007 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 0-20225 04-2711626 (State or other jurisdiction (Commission File No.) (I
November 15, 2007	EX-99.1	EX-99.1 Exhibit 99.1 ZOLL Medical Corporation Announces Record Annual Results Record Revenues and Profits for the Year CHELMSFORD, Mass.-(BUSINESS WIRE)-Nov. 15, 2007-ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced that fiscal 2007 revenues increased 21% to $309,451,000, compared to fiscal 2006 revenues of $255,633,000. Net income
November 9, 2007	SC 13G	ZOLL MEDICAL CORPORATION SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 - SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. )* ZOLL MEDICAL CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 989922109 (CUSIP Number) October 30, 2007 (Dat
November 9, 2007	EX-99	EX-99 EXHIBIT I JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.
October 10, 2007	SC 13G/A	SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.2)* ZOLL Medical Corporation - - (Name of Issuer) Common Stock, $0.01 par value - - (Title of Class of Securities) 989922109 - (CUSIP Number) September 28, 2007 - - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
August 10, 2007	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 10, 2007	SC 13G	DOC ONE SCHEDULE 13G Amendment No. 0 Zoll Medical Corporation Common Stock Cusip #989922109 Cusip #989922109 Item 1: Reporting Person - FMR Corp. Item 4: Delaware Item 5: 458,974 Item 6: 0 Item 7: 2,604,195 Item 8: 0 Item 9: 2,604,195 Item 11: 12.771% Item 12: HC Cusip #989922109 Item 1: Reporting Person - Edward C. Johnson 3d Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 2,604,195 Item 8:
July 26, 2007	EX-99.1	EX-99.1 Exhibit 99.1 ZOLL Medical Corporation Announces Third Quarter Results Achieves Record Q3 Revenue and Earnings CHELMSFORD, Mass.-(BUSINESS WIRE)-July 26, 2007-ZOLL Medical Corporation (NasdaqGS: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced revenues of $76,929,000 for the third quarter of fiscal 2007, an increase of 20% compared to revenues of $64,267,000 in
July 26, 2007	8-K	ZOLL MEDICAL CORPORATION 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 26, 2007 Date of Report (Date of earliest event reported) ZOLL MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 0-20225 04-2711626 (State or other (Commission File No.) (IRS Employer juris
June 15, 2007	11-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK REPURCHASE SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK REPURCHASE SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 þ Annual Report pursuant to Section 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2006 ¨ Transition Report pursuant to Section 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-20225 ZOLL Medical Corporation Employee Savings Plan ZOLL Medical Corporation 269 Mill Road Chelmsford, Massachusetts 01824-4105 Table of Contents REQUIRED INFORMATION ATTACHED 1.
May 11, 2007	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

ZOLL / Zoll Medical Corp - SEC-arkivering, Årsberetning, Fuldmagtserklæring

Grundlæggende statistik

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?